

Press release

Huskvarna/ Helsingborg, October 27th 2009

Natumin Pharma AB has acquired Ambria Dermatology AB.

Ambria Dermatology has developed a patented technology platform, pentane-1,5-diol, for application within the area of skincare and hygiene. The technology enables development of new products with unique features, and also enhancement of already existing products. In this way, the technology can prolong the product life cycle for existing products. Pentane-1,5-diol has an antimicrobial and antiviral effect, and extensive research and development has been conducted in order to develop new products. A considerable number of patents exist to protect the compositions and methods of pentane-1,5-diol.

Ambria originates from research at the Sahlgrenska University Hospital in Gothenburg, and has developed from idea to finished product concept in the business incubator P.U.L.S. AB since 2004. Its product concepts are documented in a number of scientific studies. Natumin and Ambria has cooperated during several years, and the product portfolio of Natumin today includes the technology of Ambria.

“For us at Natumin, it is of great value having acquired Ambria. We are planning to develop several new products within the next couple of years. These products have a great potential in the area of skin care, and our expectations on turnover are high” says Lars Karnerud, CEO of Natumin Pharma AB.

“We are happy that the technology of Ambria can continue to develop and that it can be applied in several of Natumin’s products” says Pontus Ottosson, CEO of P.U.L.S. AB

About Natumin Pharma AB

Natumin is an innovative company within research and development with production and office in south Sweden. The core of Natumin’s business is within research and documentation with a focus on natural active substances from plant extracts and oil. The products belong to the areas of food supplements, natural remedies and dermatology. Natumin’s national and international distributors are pharmaceutical- and health companies with strong positions on their markets.

About P.U.L.S. AB

P.U.L.S. AB was founded in 2002 and operates as an incubator and financier for early stage projects within life science. By adding capital, knowledge within the entire value chain –from R&D to commercialization-, and cost efficiency, the common goal of maximizing, visualizing and realizing the value of the product ideas is reached through successful sale.

Contact

Natumin Pharma: Lars Karnerud, CEO, +46 707-130740/ +46 36-39 65 50

P.U.L.S: Pontus Ottosson , CEO, +46 42-387 418